Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)GlobeNewsWire • 10/31/24
Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)GlobeNewsWire • 10/14/24
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One TreatmentGlobeNewsWire • 10/07/24
Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities ConferenceAccesswire • 09/25/24
Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business UpdateGlobeNewsWire • 08/14/24
Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL LampGlobeNewsWire • 06/24/24
Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business UpdateAccesswire • 05/15/24
Biofrontera Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock WarrantsAccesswire • 05/03/24
Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder ProposalsAccesswire • 03/26/24
CORRECTION: Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business UpdateAccesswire • 03/16/24
Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business UpdateAccesswire • 03/15/24
Biofrontera Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 15, 2024Accesswire • 03/08/24
Medicus Pharma Ltd. Announces Appointment of Erica Monaco as Chief Operating OfficerNewsfile Corp • 03/05/24
Biofrontera Inc. Announces Closing of Private Placement of up to $16.0 Million Priced at Market per Nasdaq RulesAccesswire • 02/23/24
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AGAccesswire • 02/20/24
Biofrontera Inc. Announces Private Placement of Up To $16.0 Million Priced at Market per Nasdaq RulesAccesswire • 02/20/24
Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per UseAccesswire • 02/05/24
Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2023Accesswire • 01/11/24